Hurley LH - Search Results

1

The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent.

Zewail-Foote M, Li VS, Kohn H, Bearss D, Guzman M, Hurley LH. Zewail-Foote M, et al. Among authors: hurley lh. Chem Biol. 2001 Nov;8(11):1033-49. doi: 10.1016/s1074-5521(01)00071-0. Chem Biol. 2001. PMID: 11731295

2

Molecular approaches to achieving control of gene expression by drug intervention at the transcriptional level.

Zewail-Foote M, Hurley LH. Zewail-Foote M, et al. Among authors: hurley lh. Anticancer Drug Des. 1999 Feb;14(1):1-9. Anticancer Drug Des. 1999. PMID: 10363023 Review.

3

Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove.

Zewail-Foote M, Hurley LH. Zewail-Foote M, et al. Among authors: hurley lh. J Med Chem. 1999 Jul 15;42(14):2493-7. doi: 10.1021/jm990241l. J Med Chem. 1999. PMID: 10411470

4

Differential rates of reversibility of ecteinascidin 743-DNA covalent adducts from different sequences lead to migration to favored bonding sites.

Zewail-Foote M, Hurley LH. Zewail-Foote M, et al. Among authors: hurley lh. J Am Chem Soc. 2001 Jul 11;123(27):6485-95. doi: 10.1021/ja004023p. J Am Chem Soc. 2001. PMID: 11439034

5

The antitumor agent ecteinascidin 743: characterization of its covalent DNA adducts and chemical stability.

Hurley LH, Zewail-Foote M. Hurley LH, et al. Adv Exp Med Biol. 2001;500:289-99. doi: 10.1007/978-1-4615-0667-6_46. Adv Exp Med Biol. 2001. PMID: 11764956 Review.

6

Telomeres and telomerases as drug targets.

Rezler EM, Bearss DJ, Hurley LH. Rezler EM, et al. Among authors: hurley lh. Curr Opin Pharmacol. 2002 Aug;2(4):415-23. doi: 10.1016/s1471-4892(02)00182-0. Curr Opin Pharmacol. 2002. PMID: 12127874 Review.

7

Telomere maintenance mechanisms as a target for drug development.

Bearss DJ, Hurley LH, Von Hoff DD. Bearss DJ, et al. Among authors: hurley lh. Oncogene. 2000 Dec 27;19(56):6632-41. doi: 10.1038/sj.onc.1204092. Oncogene. 2000. PMID: 11426649 Review.

8

Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription.

Siddiqui-Jain A, Grand CL, Bearss DJ, Hurley LH. Siddiqui-Jain A, et al. Among authors: hurley lh. Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11593-8. doi: 10.1073/pnas.182256799. Epub 2002 Aug 23. Proc Natl Acad Sci U S A. 2002. PMID: 12195017 Free PMC article.

9

Telomere inhibition and telomere disruption as processes for drug targeting.

Rezler EM, Bearss DJ, Hurley LH. Rezler EM, et al. Among authors: hurley lh. Annu Rev Pharmacol Toxicol. 2003;43:359-79. doi: 10.1146/annurev.pharmtox.43.100901.135733. Epub 2002 Jan 10. Annu Rev Pharmacol Toxicol. 2003. PMID: 12540745 Review.

10

The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo.

Grand CL, Han H, Muñoz RM, Weitman S, Von Hoff DD, Hurley LH, Bearss DJ. Grand CL, et al. Among authors: hurley lh. Mol Cancer Ther. 2002 Jun;1(8):565-73. Mol Cancer Ther. 2002. PMID: 12479216

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

230 results

Search Page

Filters